Anika Therapeutics Inc: Outlook FY 2024 Commercial Channel Rev up 14%-19% Excluding Revenue From Discontinued Ops
Anika Therapeutics公司:2024財年商業渠道營業收入增長14%-19%,不包括停止運營的營收
Anika Therapeutics Inc: Outlook FY 2024 Commercial Channel Rev up 14%-19% Excluding Revenue From Discontinued Ops
Anika Therapeutics公司:2024財年商業渠道營業收入增長14%-19%,不包括停止運營的營收
譯文內容由第三人軟體翻譯。